So if the results point towards readily manageable CHF, improved ejection fractions etc, plus a clear difference in adverse events at 12 months, reduced hospitalisation etc that were not there in the 2a trial at 1/6 the dose, where would the SP land?
I would expect at least some of the above otherwise why bother accepting such a late report to the conference. Something in there that could point to a change in accepted clinical practice.
All Aboard, page-4
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.055(5.34%) |
Mkt cap ! $1.230B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.09 | $1.03 | $2.294M | 2.162M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 54096 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 69414 | 5 |
View Market Depth
| Last trade - 11.09am 02/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |